Other Information
−Removed: None of the Company’s directors or officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company’s fiscal quarter ended September 30, 2023.
+Added: None of the Company’s directors or officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company’s fiscal quarter ended March 31, 2024.
Fourth Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on May 12, 2017)
2 unchanged sentences
333-214724), as amended, originally filed on November 21, 2016)
−Removed: Form of Warrant issued in April 2023 Underwritten Public Offering (incorporated by reference to Exhibit 4.2 to the Company’s Registration Statement on Form S-1/A filed on April 18, 2023)
−Removed: Form of Underwriter’s Warrant issued in April 2023 Underwritten Public Offering (incorporated by reference to Exhibit 4.3 to the Company’s Registration Statement on Form S-1/A filed on April 18, 2023)
−Removed: Form of Warrant Agency Agreement (incorporated by reference to Exhibit 4.4 to the Company’s Registration Statement on Form S-1/A filed on April 18, 2023)
Certification of Periodic Report by Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14a and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
11 unchanged sentences
ENDRA LIFE SCIENCES INC.
−Removed: November 14, 2023
/s/ Francois Michelon
3 unchanged sentences
ENDRA LIFE SCIENCES INC.
−Removed: November 14, 2023
/s/ Irina Pestrikova
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.